![Martin Brenner](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Martin Brenner
Vorstandsvorsitzender bei
IBIO, INC.
Vermögen: 58 239 $ am 31.05.2026
Profil
Martin B. Brenner currently works at iBio, Inc., as Director, Chief Executive & Scientific Officer from 2024.
Dr. Brenner also formerly worked at AstraZeneca PLC, as Senior Director & Head-BioScience from 2012 to 2013, Merck Research Laboratories Massachusetts LLC, as Executive Director-Diabetes & NASH from 2013 to 2016, Recursion Pharmaceuticals, Inc., as Chief Scientific Officer from 2017 to 2018, Pelican, Inc., as Chief Scientific Officer & Senior Vice President from 2019 to 2020, Stoke Therapeutics, Inc., as VP & Head-Research & Early Development from 2016 to 2017, and Pfizer Inc., as Head-Insulin Resistance Group.
Dr. Brenner received his doctorate degree from Ludwig-Maximilians-Universität München and doctorate degree from The University of Veterinary Medicine Hanover.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
IBIO, INC. 0.09% | 19.03.2026 | 30’652 ( 0.09% ) | 58 239 $ | 31.05.2026 |
Aktive Positionen von Martin Brenner
| Unternehmen | Position | Beginn |
|---|---|---|
| IBIO, INC. | Vorstandsvorsitzender | 20.01.2023 |
Ehemalige bekannte Positionen von Martin Brenner
| Unternehmen | Position | Ende |
|---|---|---|
| PFENEX INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.10.2020 |
| RECURSION PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2018 |
| STOKE THERAPEUTICS, INC. | Corporate Officer/Principal | 01.01.2017 |
Merck Research Laboratories Massachusetts LLC
 Merck Research Laboratories Massachusetts LLC Pharmaceuticals: MajorHealth Technology Discovers, develops, and markets a broad range of human and animal health products | Direktor/Vorstandsmitglied | 01.01.2016 |
| ASTRAZENECA PLC | Corporate Officer/Principal | 01.01.2013 |
Ausbildung von Martin Brenner
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
41
Beziehungen ersten Grades
9
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 9 |
|---|---|
Pfizer Inc.
 Pfizer Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development, manufacturing, marketing, sale and distribution of biopharmaceutical products & ingredients | Health Technology |
AstraZeneca PLC
 AstraZeneca PLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Recursion Pharmaceuticals, Inc.
 Recursion Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that combines biology, chemistry, automation, data science and engineering to industrialize drug discovery | Health Technology |
Ludwig-Maximilians-Universität München
 Ludwig-Maximilians-Universität München Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Merck Research Laboratories Massachusetts LLC
Merck Research Laboratories Massachusetts LLC Pharmaceuticals: MajorHealth Technology Discovers, develops, and markets a broad range of human and animal health products | Health Technology |
iBio, Inc.
 iBio, Inc. Pharmaceuticals: OtherHealth Technology Engages in the development and commercialization of vaccines and therapeutic proteins | Health Technology |
Pelican Inc
 Pelican Inc Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical therapeutics and vaccines | Health Technology |
The University of Veterinary Medicine Hanover
 The University of Veterinary Medicine Hanover Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Stoke Therapeutics, Inc.
 Stoke Therapeutics, Inc. BiotechnologyHealth Technology Operates as biotechnology company focused on the development of first-in-class therapeutics that selectively increase gene expression to treat genetic diseases | Health Technology |
Wählen Sie MarketScreener 
